Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Experts Believe Tainted Heparin Not Liable For Adverse Effects

This article was originally published in PharmAsia News

Executive Summary

Seven Chinese experts appointed by China's Ministry of Health and State FDA think that the adverse heparin incidents in the U.S and other countries cannot be conclusively attributed to impurities in heparin raw materials. The group met up with 11 international peers from the U.S., Australia, Denmark, Germany, France, Korea, Netherlands, Canada, Japan, Italy and Singapore to discuss heparin quality standards, testing methods, clinical side effects, source tracing and supply. Based on the following evidence, the Chinese experts surmised that the tainted heparin cannot be conclusively linked to the side effects. Injections produced by American firms Covidien and B.Braun, which used tainted heparin raw materials from China did not give rise to any bad reaction; on the other hand, some batches of Baxter's injections without the ingredients had caused serious side effects. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel